Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for Hemophilia A and B With or Without Inhibitors

 Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for Hemophilia A and B With or Without Inhibitors

Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for Hemophilia A and B With or Without Inhibitors

Shots:

  • Novo Nordisk has paused its two P-III clinical studies (explorer7 and 8) and one P-II clinical study (explorer5) investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status
  • The studies have been paused due to the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing P-III program. Novo Nordisk and DMC are evaluating the relevance of the events for the continuation of the program, yet no conclusions have been made
  • In Oct’2019, P-III explorer7 has initiated to establish the safety and efficacy of concizumab (qd, SC) delivered in a pen device for reducing the number of bleeds. The explorer8 study was initiated in Nov’2019 which enroll ~293 patients from 32 countries while P-II explorer5 study was started in Oct’2017

Click here to­ read full press release/ article | Ref: Novo Nordisk | Image: The Diabetes Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post